WA
DFTX

Wealth Alliance’s Definium Therapeutics DFTX Stock Holding History

Wealth Alliance’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,000
Closed -$62.6K – 525
2024
Q3 		$62.6K Hold
11,000
– – 0.01% 517
2024
Q2 		$79.3K Buy
+11,000
New +$96.2K 0.01% 505

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Alliance's DFTX Position: Q4 2024 in Review

Wealth Alliance sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 11,000 shares — an estimated $62.6K sold.

Wealth Alliance first reported a position in DFTX in Q2 2024 and held it in 2 quarters. The position peaked at $79.3K in Q2 2024. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Wealth Alliance reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Wealth Alliance sold 11,000 Definium Therapeutics shares in Q4 2024, an estimated $62.6K.
  • Wealth Alliance first reported a position in Definium Therapeutics in Q2 2024 and held it in 2 quarters.
  • Wealth Alliance's Definium Therapeutics position peaked at $79.3K in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Wealth Alliance's 13F filing for Q4 2024, filed 3 Feb 2025.